Novel small-molecule tyrosine-kinase inhibitors (TKI) directed specifically against the BCR-ABL gene has changed CML from a cancer with high mortality to largely a chronic disease managed with medications (147). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.